Key result
Log-transformed NT-proBNP was an independent predictor of reduced left ventricular ejection fraction in patients with chronic kidney disease (OR 2.37), with stage-specific cut-offs improving diagnostic accuracy.
Why the study?
A single diagnostic threshold of NT-proBNP for detecting systolic dysfunction in patients with CKD is inadequate.
Does NT-proBNP accurately identify reduced LVEF in patients with CKD stages 3-5?
Observational (n=840)
No
Does NT-proBNP accurately identify reduced LVEF in patients with CKD stages 3-5?
NT-proBNP is a useful marker for detecting systolic dysfunction in CKD patients, but stage-specific cut-off values are necessary to improve diagnostic precision.
Stage-specific NT-proBNP thresholds may aid LVEF screening in CKD; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Interpreting N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in chronic kidney disease (CKD) is challenging due to reduced renal clearance and frequent cardiovascular comorbidities. This study evaluated the diagnostic accuracy of NT-proBNP for identifying reduced left ventricular ejection fraction (LVEF < 50%) across different CKD stages. METHODS: This retrospective study included 840 patients with CKD Stages 3-5. Patients were categorized into reduced ejection fraction (REF, LVEF < 50%; n = 114) and preserved ejection fraction (PEF, LVEF ≥ 50%; n = 726) groups. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis, and stage-specific optimal cut-off values were determined by Youden's J statistic. Multivariate logistic regression was used to identify independent predictors of reduced LVEF. RESULTS: Median NT-proBNP levels were significantly higher in the REF group than in the PEF group (2,962 vs. 437 pg/mL, p < 0.001). In the overall cohort, NT-proBNP demonstrated good diagnostic performance (AUC: 0.805), with an optimal cut-off value of 1,562 pg/mL yielding 71.3% sensitivity and 77.8% specificity. Diagnostic accuracy differed according to renal function, being highest in Stage 3a (AUC: 0.872) and lowest in Stage 5 (AUC: 0.647). Optimal thresholds increased progressively with advancing CKD: 694 pg/mL (Stage 3a), 1,452 pg/mL (Stage 3b), 1,562 pg/mL (Stage 4), and 2,121 pg/mL (Stage 5). In multivariate analysis, log-transformed NT-proBNP remained an independent predictor of reduced LVEF (OR: 2.37, 95% CI: 1.96-2.86, p < 0.001), after adjustment for potential confounders including atrial fibrillation and valvular heart disease. CONCLUSIONS: NT-proBNP is a useful marker for detecting systolic dysfunction in patients with CKD. However, a single diagnostic threshold is inadequate; stage-specific cut-off values improve diagnostic precision, particularly in early-to-moderate CKD, and may facilitate earlier referral for echocardiographic evaluation.
No takes yet. Share an insight, caveat, or question.
Eren et al. (2026) conducted an observational in Chronic Kidney Disease (n=840). NT-proBNP vs. Preserved left ventricular ejection fraction (LVEF ≥ 50%) was evaluated on Reduced left ventricular ejection fraction (LVEF < 50%) (OR 2.37, 95% CI 1.96-2.86, p=<0.001). Log-transformed NT-proBNP was an independent predictor of reduced left ventricular ejection fraction in patients with chronic kidney disease (OR 2.37), with stage-specific cut-offs improving diagnostic accuracy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: